IgA肾病药物收入同比增长1581% 2024年云顶新耀首次实现商业化层面盈利,仍净亏损10亿元

每日经济新闻
27 Mar

3月26日,云顶新耀(HK01952,股价53.9港元,市值176亿港元)发布2024年度业绩报告。报告显示,公司全年收入达7.07亿元,同比增长461%,超额完成7亿元既定目标。同时,云顶新耀表示,公司首次实现了年度商业化层面的盈利。云顶新耀的商业化层面盈利,主要得益于三款已上市产品的商业化落地。其中,全球首个对因治疗IgA肾病(一种肾小球疾病)药物耐赋康年内实现3.534亿元收入,同比增长...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10